Day: May 3, 2021

Appointment adds to the Nanox team extensive experience in global medical business development and sales NEVE ILAN, Israel, May 03, 2021 (GLOBE NEWSWIRE) — NANOX IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, announced today the appointment of Moshe Shtengel as Chief Business Officer, effective May 2, 2021. Mr. Shtengel joins Nanox from Tuttnauer, a global manufacturer of sterilizers and infection control systems for medical institutions, where he served as Vice President of Global Sales, Marketing and Products. “Moshe is an extremely seasoned sales and business development executive with a proven track record of success and leadership in the medical field,” stated Ran Poliakine, Chairman and Chief Executive Officer of Nanox. “As we ramp up our manufacturing capabilities...

BURLINGTON, Mass., May 03, 2021 (GLOBE NEWSWIRE) — Cerence Inc. (NASDAQ: CRNC), AI for a world in motion, will announce its second quarter, fiscal year 2021 financial results for the quarter ended March 31, 2021 on Monday, May 10, 2021 at 7:00 a.m. EST / 4:00 a.m. PST. The company will host a live conference call and webcast, with accompanying slides to discuss the results, on the same day at 10:00 a.m. Eastern Time / 7:00 a.m. Pacific Time. Interested investors and analysts are invited to dial into the conference call by using 1.844.467.7116 (domestic) or +1.409.983.9838 (international) and entering the pass code 7998527. Webcast access will be available in the Investor Information section of the company’s website at www.cerence.com. The teleconference replay will be available through May 17, 2021. The replay dial-in number is...

CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will host a conference call and webcast on Monday, May 10, 2021 at 4:30 p.m. ET to report financial results for the first quarter ended March 31, 2021 and provide business updates.   To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 5046849. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com. About Mersana TherapeuticsMersana Therapeutics is a clinical-stage biopharmaceutical company using...

CALABASAS, Calif., May 03, 2021 (GLOBE NEWSWIRE) — NETSOL Technologies, Inc. (Nasdaq: NTWK), a global business services and enterprise application solutions provider, will hold a conference call on Thursday, May 13 at 9:00 a.m. Eastern time (6:00 a.m. Pacific time) to discuss results for the fiscal third quarter ended March 31, 2021. Financial results will be issued in a press release prior to the call. NETSOL management will host the presentation, followed by a question and answer period. Date: Thursday, May 13, 2021Time: 9:00 a.m. Eastern time (6:00 a.m. Pacific time)U.S. dial-in: 1-877-407-0789International dial-in: 1-201-689-8562 Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call,...

QUEBEC CITY, May 03, 2021 (GLOBE NEWSWIRE) — (TSXV: HEO) – H2O Innovation Inc. (“H2O Innovation” or the “Corporation”) is pleased to announce its continued expansion in (“LATAM”), and increased efforts in the North American water reuse market, executing on several key objectives from the Corporation’s 3-Year Strategic Plan. In line with the recently announced acquisition of Genesys Membrane Products S. L. (“GMP”), which added an office for the Corporation in Santiago, Chile, H2O Innovation will strengthen existing and generate new relationships with original equipment manufacturers (“OEM”) in LATAM, a high growth potential market. With Piedmont having recently signed Pavax as a new distributor in Brazil, the Corporation’s Specialty Products pillar has now over 20 distributors in LATAM. A Key Account strategy is being implemented...

LONDON, United Kingdom, May 03, 2021 (GLOBE NEWSWIRE) — Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announces the appointment of Julie O’Neill as a Non-Executive Director to the Board and Markwin Velders, Ph.D. to its Scientific Advisory Board (SAB). Both individuals come to Achilles with strong track records of experience in cell therapy and cell therapy manufacturing. Ms. O’Neill is a business professional with more than two decades of executive experience in senior leadership roles. She was previously Executive Vice President, Global Operations at Alexion Pharmaceuticals. where she led the Global Operations business including product development, manufacturing, quality, supply chain and global real estate functions. Prior...

MISSISSAUGA, Ontario, May 03, 2021 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that for the sixth consecutive year, FeraMAX® has been named the #1 recommended iron supplement brand in a national survey of Canadian physicians and pharmacists. The 2021 OTC Recommendations Survey was conducted by EnsembleIQ, Research, Insights and Innovation team and the following publications and websites: Pharmacy Practice + Business, The Medical Post, Profession Santé, CanadianHealthcareNetwork.ca and ProfessionSanté.ca. This annual survey was conducted online between October 2020 and January 2021 with Canadian retail pharmacists and physicians. In total, 1,812 surveys were completed by pharmacists (including 647 Québec pharmacists) and 657 surveys were completed by physicians (including 268 Québec physicians). FeraMAX®...

Former Director of Healthcare Partnerships and External Relations at Linde plc brings 26 years of experience to Beyond Air GARDEN CITY, N.Y., May 03, 2021 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced the appointment of Peter Senior to Director of Business Development. “I am thrilled to welcome Peter to Beyond Air at such a pivotal moment for the company,” said Steve Lisi, Chairman and Chief Executive Officer of Beyond Air. “Peter provides us with essential nitric oxide experience, bringing with him a wealth of knowledge of...